Loading clinical trials...

A Study of Implantation of CRENEOUS ENTERPRISE 2 Intracranial Stent in Participants With Severe Symptomatic Intracranial Atherosclerotic Stenosis | Clinical Trials | Clareo Health

RECRUITINGNA

A Study of Implantation of CRENEOUS ENTERPRISE 2 Intracranial Stent in Participants With Severe Symptomatic Intracranial Atherosclerotic Stenosis

Implantation of CERENOVUS ENTERPRISE 2 Intracranial Stent in Patients With Severe Symptomatic Intracranial Atherosclerotic Stenosis: A Multicenter, Prospective and Single-Arm Study in China

NCT05316311•Medos International SARL

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety and effectiveness of CERENOVUS ENTERPRISE 2 intracranial stent implantation in treatment of participants with severe symptomatic intracranial atherosclerotic stenosis.

Eligibility

Age

22 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participants aged 22-80 years old
•All participants are required to meet at least one additional criteria (a-f) provided below to qualify for the study; (a) insulin dependent diabetes for at least 15 years; (b) at least 2 of the following atherosclerotic risk factors: hypertension (blood pressure \[BP\] greater than or equal to \[\>=\] 140/90 or on antihypertensive therapy); dyslipidemia (low density lipoprotein \[LDL\] 130 milligrams per deciliter \[mg/dl\] or high density lipoprotein \[HDL\] less than \[\<\] 40 mg/dl or fasting triglycerides \>= 150 mg/dl or on lipid lowering therapy); smoking; abnormal glucose metabolism (fasting blood glucose \>= 6.2 millimole per liter (mmol/L) or 2 hours postprandial blood glucose \>= 7.8mmol/L); family history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, stroke, carotid endarterectomy or stenting, peripheral vascular surgery in parent or sibling who was \<55 years of age for men or \<65 for women at the time of the event ; (c) history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, carotid endarterectomy or stenting, or peripheral vascular surgery for atherosclerotic disease ; (d) any stenosis of an extracranial carotid or vertebral artery, another intracranial artery, subclavian artery, coronary artery, iliac or femoral artery, other lower or upper extremity artery, mesenteric artery, or renal artery that was documented by non-invasive vascular imaging or catheter angiography and is considered atherosclerotic ; (e) Aortic arch atheroma or atherosclerotic aortic aneurysm documented by non-invasive vascular imaging or catheter angiography ; (f) High resolution magnetic resonance imaging (MRI) imaging confirmed the presence of atherosclerotic plaques in the target arterial stenosis
•Participants with symptomatic intracranial atherosclerotic stenosis who is receiving medical treatment (that is, receiving at least one antithrombotic medication and vascular risk factor management) but still had recurrent (2 or more) ischemic strokes during the medical treatment period within past year
•Vascular diameter proximal to the stenosis must be measured at 2.0-4.0 millimeters (mm)
•Modified Rankin Scale (mRS) \<= 2
•Stenosis of 70%-99% on non-invasive vascular imaging or digital subtraction angiography (DSA), with normal distal vessel
•Participant is willing and able to return for all follow-up visits required by the protocol
•Participants understand the purpose and requirements of the study and have signed an informed consent form Intra procedure
•Stenosis of 70 percent (%) -99% on digital subtraction angiography (DSA), with normal distal vessel

Exclusion Criteria

•Participant underwent an acute ischemic stroke within 2 weeks
•Participants in whom one stent can't cover the lesion length or the use of multiple stents is required
•Greater than (\>) 50% stenosis proximal or distal to the target intracranial lesion
•Intracranial arterial stenosis related to non-atherosclerotic factors, such as: arterial dissection, moya-moya disease; vasculitic disease; herpes zoster, varicella zoster or other viral vasculopathy; neurosyphilis; any other intracranial infection; any intracranial stenosis associated with cerebrospinal fluid pleocytosis; radiation-induced vasculopathy; fibromuscular dysplasia; sickle cell disease; neurofibromatosis; benign angiopathy of central nervous system; postpartum angiopathy; suspected vasospastic process, and developmental or genetic abnormalities
•Participants with symptoms of cerebral ischemia caused by cardiac embolism
•Severe vascular tortuosity, highly calcified or anatomy that would preclude the safe introduction of a guiding catheter, guiding sheath or stent placement
•Myocardial infarction within previous 30 days
•Permanent atrial fibrillation, persistent atrial fibrillation, any episode of paroxysmal atrial fibrillation within the past six months, or history of paroxysmal atrial fibrillation requiring chronic anticoagulation
•Intolerance or allergic reaction to any of antithrombotic therapy or medicine used during the procedure
•History of life-threatening allergy to contrast medium. If not life threatening and can be effectively pre-treated, participant can be enrolled at investigators' discretion
+7 more criteria

Locations (14)

Xuanwu Hospital, Capital Medical University

Beijing, China

West China Hospital of Sichuan University

Chengdu, China

Haikou People's Hospital

Haikou, China

First Affiliated Hospital, Harbin Medical University

Harbin, China

Central Hospital Affiliated to Shandong First Medical University (Jinan Central Hospital)

Jinan, China

Qilu Hospital of Shandong University

Jinan, China

Shandong Provincial Hospital

Jinan, China

Nanjing Drum Tower Hospital

Nanjing, China

Ningbo First Hospital

Ningbo, China

Huashan Hospital Fudan University

Shanghai, China

Key Dates

Start Date

May 24, 2022

Primary Completion Date

December 24, 2025

Completion Date

April 11, 2026

Last Updated

March 13, 2026

Enrollment

194

ESTIMATED participants

Conditions

Intracranial Atherosclerosis

Interventions

CERENOVUS ENTERPRISE 2 Intracranial Stent

DEVICE

Contacts

Jie ZHOU

CONTACT

86 18600551010 jzhou138@its.jnj.com

PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis

NCT06902740

Intracranial AtherosclerosisIntracranial Artery Stenosis+1 more

View study

RECRUITINGNA

Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial

NCT04948749

ICAD - Intracranial Atherosclerotic DiseaseICAS - Intracranial Atherosclerosis+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 13, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Implantation of CRENEOUS ENTERPRISE 2 Intracranial Stent in Participants With Severe Symptomatic Intracranial Atherosclerotic Stenosis

Inclusion Criteria

Exclusion Criteria

PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis

Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial

ICAS Screen Based on RIC

Optical Coherence Tomography for Intracranial Atherosclerotic Stenosis

AcoArt sICAS: DCB in the Treatment of Symptomatic Intracranial Atherosclerotic Stenosis

IntraCranial Angiography-derived Fraction Flow-guided Percutaneous Transluminal Angioplasty and Stenting Versus Medical Therapy (ICAS-MT)